Opinion
Video
Ensifentrine (ENHANCE Trials) in COPD
Panelists discuss how the ENHANCE trials assessed ensifentrine in patients with chronic obstructive pulmonary disease (COPD) with moderate-to-severe airflow obstruction and a history of exacerbations. Outcomes showed improved lung function and reduced exacerbations. Clinically, ensifentrine may be used as monotherapy or an add-on, addressing diverse patient needs.
Video content above is prompted by the following:
- Ensifentrine is recommended in the 2025 GOLD Report as a bronchodilator to improve dyspnea. Ensifentrine is also suggested as a potential anti-inflammatory therapy in stable COPD.
- What were the main patient eligibility criteria and clinical outcomes in the ENHANCE trials?
- How do you anticipate that ensifentrine will be used in clinical practice (ie, monotherapy, add-on, both)?
Related Videos
Related Content
